KRISPY KREME ($DNUT) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.05 per share, missing estimates of -$0.05 by $0.00. The company also reported revenue of $375,180,000, missing estimates of $392,063,520 by $-16,883,520.
You can see Quiver Quantitative's $DNUT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KRISPY KREME Insider Trading Activity
KRISPY KREME insiders have traded $DNUT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DNUT stock by insiders over the last 6 months:
- INDULGENCE B.V. JAB sold 694,445 shares for an estimated $3,000,002
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KRISPY KREME Hedge Fund Activity
We have seen 79 institutional investors add shares of KRISPY KREME stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BNP PARIBAS FINANCIAL MARKETS added 15,337,898 shares (+inf%) to their portfolio in Q4 2024, for an estimated $152,305,327
- BAMCO INC /NY/ added 2,588,398 shares (+24.7%) to their portfolio in Q4 2024, for an estimated $25,702,792
- COOPER CREEK PARTNERS MANAGEMENT LLC added 2,186,136 shares (+43.0%) to their portfolio in Q4 2024, for an estimated $21,708,330
- SAMLYN CAPITAL, LLC removed 1,757,948 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $17,456,423
- WOODLINE PARTNERS LP removed 1,324,960 shares (-78.7%) from their portfolio in Q4 2024, for an estimated $13,156,852
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 1,321,213 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $13,119,645
- BARROW HANLEY MEWHINNEY & STRAUSS LLC added 1,066,540 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,590,742
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
